PMcardio receives FDA Breakthrough Device Designation — read the full story

PM Magazine

Powerful Medical Receives FDA Breakthrough Device Designation for PMcardio STEMI AI ECG Model

Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention.

Editor's Choice

Collage showing a conference speaker, PMcardio app UI, hospital partnerships across Europe, and a research award ceremony.

May Highlights from Powerful Medical: PMcardio 3.0 Launch, STEMI Research, and Clinical Breakthroughs

Introducing PMcardio for Individuals 3.0: A New Era in AI-Powered Second Opinions for ECG Interpretation

Introducing PMcardio for Individuals 3.0: A New Era in AI-Powered Second Opinions for ECG Interpretation

Winners+of+AHA's+Health+Tech+Competition+2024

Powerful Medical Wins Best Science Pitch and Overall Winner at AHA Health Tech Competition 2024

Collage showing a conference speaker, PMcardio app UI, hospital partnerships across Europe, and a research award ceremony.

May Highlights from Powerful Medical: PMcardio 3.0 Launch, STEMI Research, and Clinical Breakthroughs

May was a milestone month at Powerful Medical. From launching PMcardio for Individuals 3.0 and showcasing new explainable AI tools, to advancing STEMI detection through international research and clinical collaboration—discover the breakthroughs that are shaping the future of cardiac care.

ECGxplain™: The Explainability Feature in PMcardio -With Human-Centered Design in Mind

In high-stakes emergency and cath lab settings, every second counts when diagnosing acute myocardial infarctions. PMcardio’s Explainability feature brings unmatched transparency to AI-powered ECG analysis, empowering clinicians with clear, trustworthy insights for faster, more confident decision-making.

Announcing the AI-ECG TIMI Study: A Multi-Center Validation

We are thrilled to announce the launch of the AI-ECG TIMI Study, a novel, international, multi-center observational study aimed at validating the use of AI to improve the detection and management of acute coronary syndromes (ACS).

PMcardio Steals the Show at AHA 2024, Demonstrating High Accuracy with 5 Clinical Validation Studies

The American Heart Association (AHA) conference is one of the most anticipated cardiology events in the world, bringing together 15,000 to 18,000 attendees each year—from trailblazing researchers to frontline clinicians and innovators shaping the future of heart health.

Stay on the pulse with our newsletter

Your submission was successful